Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism

Gerard Aragonès1, Carlos Alonso-Villaverde2, Pedro Pardo-Reche3, Anna Rull1, Raúl Beltrán-Debón1, Esther Rodríguez-Gallego1, Laura Fernández-Sender1,3, Jordi Camps1 and Jorge Joven1*

Abstract

Background: The recently observed association between the APOC3-related rs10892151 polymorphism and serum triglyceride levels has prompted us the possibility to explore whether this genetic variant may play a major role in human immunodeficiency virus (HIV)/antiretroviral therapy-induced dyslipidemia.

Methods: We determined the rs10892151 genotype distribution and serum apolipoprotein (apo) C-III concentration in a group of HIV-infected patients (n = 208) and in a group of age and sex-matched healthy volunteers (n = 200). Circulating lipid and lipoprotein levels were followed for 12 months after antiretroviral treatment initiation in the HIV-infected group.

Results: There were no significant variations in the frequency of the A allele between the healthy and HIV-infected groups (7.5 vs. 8.6%, respectively; p = 0.7); additionally, the A allele was not related to serum apo C-III concentration. However, among patients receiving protease inhibitor (PI) treatment, carriers of the A allele had significantly increased serum triglyceride (5.76 ± 2.54 mmol/L) and total cholesterol (6.63 ± 2.85 mmol/L) concentrations together with depressed levels of HDL-cholesterol (0.75 ± 0.3 mmol/L) when compared with patients not carrying the allele (2.43 ± 1.32, 5.2 ± 2.17 and 1.24 ± 0.4 mmol/L, respectively) at the end of the study. This effect was only evident for HDL-cholesterol concentration when patients were treated with non-nucleoside reverse transcriptase inhibitors (1.05 ± 0.4 vs. 1.28 ± 0.4 mmol/L).

Conclusions: The A allelic variant of the rs10892151 polymorphism is not associated with serum apo C-III concentration, but predisposes HIV-infected patients to less favorable lipid profile, particularly in those patients treated with PIs.

Background

The introduction of antiretroviral therapies has led to a remarkable increase in the life expectancy of patients with human immunodeficiency virus (HIV) infection. Unfortunately, current treatment may cause a wide spectrum of metabolic disturbances and comorbid conditions, with cardiovascular disease as an important example [1]. Dyslipidemia is particularly frequent and is mostly characterized by hypertriglyceridemia and low HDL-cholesterol concentrations. Although this phenomenon has been attributed, at least in part, to the use of protease inhibitors (i.e., ritonavir or ritonavir-boosted treatment), dyslipidemia is also observed in treatment-naïve HIV-infected patients, suggesting that HIV infection itself has a metabolically deleterious effect [2,3].

Susceptibility to developing these metabolic derangements, specifically hypertriglyceridemia, varies among individuals and could be influenced by genetic variability [4]. In an attempt to find new candidate genes responsible for variations in lipid concentrations, we have explored the rs10892151 polymorphism, which is located within an intron of the DSCAML1 (Down syndrome cell adhesion molecule like-1) gene and is in
linkage disequilibrium with a loss-of-function mutation in the APOC3 gene. Carriers of this null mutation have low circulating apolipoprotein (apo) C-III levels and reduced fasting and post-prandial triglyceride concentrations [5], which is likely due to the well-established function of apo C-III as an inhibitor of lipoprotein lipase [6]. Other functions attributed to apo C-III include a reduction in the hepatic uptake of apo B-containing lipoproteins [7,8] as well as an increase in the catabolism of high-density lipoprotein (HDL) particles [9], adhesion of monocytes to vascular endothelial cells [10], and the activation of inflammatory signaling pathways [11].

Because HIV-associated dyslipidemia is accompanied by increases in apoB-containing lipoproteins, impaired lipolysis, and decreases in HDL-cholesterol levels [12], we hypothesized that in HIV-infected patients, the rs10892151 polymorphism could be an important genetic factor influencing the deleterious effect of HIV on lipid profile. Hence, we investigated treatment-induced lipid and lipoprotein changes in HIV-infected patients who were segregated with respect to their treatment strategy and their rs10892151 genotype.

**Methods**

**Subjects and study design**

We recruited patients from among the participants of a longitudinal project assessing atherosclerosis in HIV-infected patients [13,14] from January 2001 through December 2004; all subjects agreed to participate in the present study and provided informed consent. The initial time-point of this study was the commencement of therapy with protease inhibitors (PIs) or with non-nucleoside reverse transcriptase inhibitors (NNRTIs) based schemes. The antiretroviral adjuvant drugs were zidovudine, lamivudine or stavudine. Follow-up was conducted at 3, 6, and 12 months after treatment initiation. Candidates for inclusion were naïve patients, and patients previously exposed to antiretroviral treatment who had discontinued treatment for at least 6 months. No patient was being treated with lipid-lowering drugs at the commencement of the study, but 20 patients were treated with fluvastatin (80 mg/day) during the follow-up. For the purpose of this study, only patients who remained on the same antiretroviral treatment regimen during follow-up were included in the analysis. For the control group, we selected 200 age and sex-matched healthy volunteers who participated in an epidemiological study, the details of which have been previously reported [15]. The study was approved by the Ethics Committee of the Hospital Universitari de Sant Joan de Reus.

**Clinical and Laboratory Measurements**

Detailed clinical characteristics of each subject were recorded, and a thorough physical examination was performed during the interview. We recorded data regarding HIV infection, including opportunistic infections, mode of HIV transmission, CD4+ T cell count, HIV viral load, presence of lipodystrophy and HCV co-infection status. Body mass index (BMI) was defined as weight (kg)/height$^2$ (m$^2$). Fasting serum glucose, cholesterol, triglycerides, highly sensitive C-reactive protein (CRP) and apo C-III concentrations were measured with the LXi 725-Synchron (Beckman Coulter, Fullerton, California, USA) automatic analyzer using enzymatic assays or chemiluminescent immunoassays. HDL- and LDL-cholesterol levels were measured as described [16,17]. Serum concentration of monocyte chemotactic protein-1 (MCP-1) was measured with an enzyme-linked immunosorbent assay (Human MCP-1 ELISA, PeproTech, London, UK).

**Genotyping**

Participants were genotyped for the rs10892151 polymorphism using the TaqMan 5' allelic discrimination assay by the custom TaqMan SNP Genotyping Assay C_3239453_10 (Applied Biosystems, Foster City, CA) [18]. Amplifications were performed in a 7900HT Sequencing Detection System (Applied Biosystems) for continuous fluorescence monitoring.

**Statistical analyses**

Analysis was performed using SPSS, version 18.0 (SPSS Inc., Chicago, IL). All data are presented as mean ± SD, except where otherwise stated. The Kolmogorov-Smirnov test was used to check whether data were normally distributed. The Hardy-Weinberg equilibrium (HWE) for the SNP was tested with the $\chi^2$ test. Allele and genotype frequencies between cases and controls were compared with the $\chi^2$ analysis. Differences in baseline characteristics between the two treatment groups were assessed through the $\chi^2$ and Mann-Whitney $U$ test for categorical and continuous variables, respectively. To assess whether changes in lipid levels at months 0, 3, 6, and 12 were significantly different from baseline in each treatment group, and whether those changes were significantly different between the two treatment groups, we used linear mixed models including the interaction between treatment group and month of therapy as categorical. Linear mixed models allowed us to accommodate multiple measures per person. Univariate and multivariate analyses were performed, with adjustment for confounding factors such as sex, age, BMI, co-infection with HCV, lipodystrophy and lipid-lowering therapy.
Results

Characteristics of participants

Of 208 Caucasian subjects who met selection criteria, 113 (54.3%) initiated NNRTI and 95 (45.7%) PI based scheme. The second component of the regimen were two non nucleoside reverse transcriptase inhibitor [zidovudine (70.2%), lamivudine (91.3%) or stavudine (38.5%)] in patients treated with NNRTI, and zidovudine (77.8%), lamivudine (84.8%) or stavudine (37.4%) in patients treated with PI; \( p = 0.8 \). Of the 208 patients initially selected, 201, 198 and 192 of them remained on the same ART regimen at months 3, 6 and 12 of follow-up, respectively. 160 (76.9%) were treatment-naïve patients (95 in NNRTI group and 65 in the PI group, \( p = 0.62 \)), and 48 (23.1%) were patients reintimating antiretroviral therapy after treatment interruption for at least 6 months (18 in NNRTI group and 30 in the PI group, \( p = 0.79 \)).

The baseline clinically relevant characteristics of the patients included in the study are summarized in Table 1. The mean time from diagnosis was 7.24 ± 0.36 years, and 133 (63.9%) patients were co-infected with hepatitis C virus. These patients were either current or past intravenous drug users (60.1%) or became infected as a result of sexual intercourse. The baseline examination revealed that most patients were heavy smokers, were relatively young, were not significantly obese and had normal blood pressure values.

Table 1 Baseline main clinical and demographic characteristics of HIV-infected patients based on rs10892151 genotype

| Characteristics at study entry | G/G carriers \((n = 190)\) | A/G carriers \((n = 18)\) |
|-------------------------------|-----------------|-----------------|
| Age, years                    | 39.1 (6.9)      | 37.9 (7.0)      |
| Gender, n (%)                 | Male            | Female          |
|                               | 127 (66.8)      | 63 (33.2)       |
|                               | 13 (72.2)       | 5 (27.8)        |
| BMI, kg/m²                    | 22.74 (2.9)     | 23.23 (3.6)     |
| Risk factors for HIV, n (%)   | Intravenous drug use | 114 (60.0) |
|                               | 11 (61.1)       | 57 (30.0)       |
|                               | 5 (27.7)        | 19 (10.0)       |
|                               | 2 (11.2)        | 113 (60.5)      |
|                               | 13 (72.2)       | HIV-1 RNA viral load, copies/mL |
|                               | 246582 (776921) | 336652 (863524) |
| CD4+ T cell count, cells/\(\mu L\) | 448.9 (285.9)  | 435.1 (290.9)   |
| Treatment scheme, n (%)       | NNRTI based     | 103 (54.2)      |
|                               | 10 (55.5)       | 87 (45.8)       |
|                               | PI based        | 11.27 (4.9)     |
|                               | 10.42 (4.7)     | 8 (44.5)        |
|                               | Total cholesterol, mmol/L | 4.89 (1.2)     |
|                               | 4.80 (1.2)      | 1.06 (0.4)      |
|                               | HDL-cholesterol, mmol/L | 1.08 (0.4)     |
|                               | 0.87 (0.3)      | 2.91 (0.9)      |
|                               | Triglycerides, mmol/L | 2.48 (2.0)     |
|                               | 2.40 (2.0)      | 2.48 (2.0)      |
|                               | Glucose, mmol/L | 5.39 (0.9)      |
|                               | 5.51 (1.0)      | 4.13 (5.4)      |
|                               | CRP, mg/L       | 4.91 (6.2)      |
|                               | 74.72 (41.8)    | 81.17 (43.1)    |

Values are the mean and the standard deviation (SD), unless otherwise indicated. BMI, body-mass index

rs10892151 genotype distribution

The genotype and allelic frequencies of the rs10892151 polymorphism did not show significant variations between healthy and HIV-infected participants \( p = 0.7 \). A total of 18 subjects (8.6%) from the HIV-infected group and 15 (7.5%) from the healthy group were carriers of the A allele, while 190 (91.4%) HIV-infected patients and 185 (92.5%) healthy subjects were carriers of two G alleles (the wild-type genotype). No subjects were homozygous for the A allele. The A allelic frequency for these populations was similar to that reported in the National Center for Biotechnology Information SNP public database; it was not significantly different to that predicted by the Hardy-Weinberg distribution.

When we examined serum apo C-III concentration based on genotypes, no statistically significant differences were observed in serum apo C-III levels among healthy participants [9.21 (3.7) \( \mu g/mL \) in G/G carriers versus 8.91 (3.5) \( \mu g/mL \) in A/G carriers; \( p = 0.8 \)] or among HIV-infected patients [10.49 (4.8) \( \mu g/mL \) in G/G carriers versus 10.34 (4.8) \( \mu g/mL \) in A/G carriers; \( p = 0.7 \)]. We also failed to observe significant associations between the duration and nature of antiretroviral treatment or viral load and serum apo C-III concentration as well as between lipid profile and rs10892151 genotype distribution in healthy participants.

Effects of rs10892151 polymorphism on metabolic variables

Table 2 depicts the main baseline characteristics of HIV-infected patients segregated according to rs10892151 genotype variants and treatment scheme. No significant differences were observed between groups for the variables considered here. It was only in the subset of HIV-infected patients without HCV co-infection that carriers of the A allele displayed a trend towards a favorable lipid profile when compared to non-carriers; however, this difference did not reach statistical significance (data not shown).

Course of lipid disturbances in patients receiving either PI or NNRTI therapy

Because hyperlipidemia is strongly associated with the PI treatment regimen, we focused on a subgroup of 95 patients receiving PIs as a component of their antiretroviral therapy, and we analyzed lipid profile changes over time.
Table 2 Baseline main metabolic characteristics of HIV-infected patients based on rs10892151 genotype and treatment strategy

|                     | PI-treated patients | NNRTI-treated patients |
|---------------------|---------------------|------------------------|
|                     | G/G carriers | A/G carriers | G/G carriers | A/G carriers |
| (n = 93)         | (n = 87)   | (n = 8)     | (n = 103)    | (n = 10)     |
| BMI, kg/m²         | 22.9 (3.1) | 23.4 (3.2) | 22.6 (2.9)  | 23.1 (3.1)  |
| ApoC-III, μg/mL    | 11.12 (5.1) | 10.62 (4.6) | 11.39 (4.9) | 10.26 (4.8) |
| Total cholesterol, mmol/L | 4.91 (1.3) | 5.06 (1.3) | 4.87 (1.2)  | 4.60 (1.2)  |
| HDL-cholesterol, mmol/L | 1.02 (0.4) | 1.06 (0.4) | 1.09 (0.4)  | 1.1 (0.4)   |
| LDL-cholesterol, mmol/L | 0.82 (0.2) | 0.54 (0.1) | 0.91 (0.4)  | 0.72 (0.3)  |
| VLDL-cholesterol, mmol/L | 2.82 (0.8) | 2.87 (0.9) | 2.88 (0.9)  | 2.95 (0.9)  |
| Triglycerides, mmol/L | 2.65 (2.1) | 2.78 (2.2) | 2.34 (2.2)  | 2.10 (2.1)  |
| Glucose, mmol/L     | 5.68 (1.0) | 5.95 (0.9) | 5.15 (0.9)  | 5.16 (0.9)  |
| CRP, mg/L           | 4.6 (5.4)   | 5.1 (5.8)   | 3.73 (5.5)  | 4.76 (5.7)  |
| MCP-1, pg/mL        | 73.31 (40.3) | 78.76 (43.8) | 75.92 (42.1) | 83.10 (44.8) |

Values are the mean and the standard deviation (SD), unless otherwise indicated. BMI, body-mass index; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor

Discussion

Our study represents the first report of a strong association between the rs10892151 A allelic variant and the expression, particularly during PI-treatment, of a dyslipidemic phenotype in HIV-infected patients, which includes hypertriglyceridemia and depressed HDL-cholesterol levels.

The high prevalence of lipid disorders among treated HIV-infected patients requires the identification of specific polymorphisms in candidate genes that might predispose to these complications. However, the genetic basis of these metabolic abnormalities remains unclear. Some studies show that variants of apo A-V and C-III, interacting with APOE genotypes, are associated with the severity of antiretroviral treatment-induced dyslipidemia. For instance, the most severe dyslipidemic profiles after PI therapy were obtained in those patients carrying the three APOC3 variations (i.e., at nucleotides -455, -482 and the SstI site) and a non-ε2/ε3 APOE genotype [19-21]. Similarly, Guardiola et al. [22] indicated that in a cohort of PI treated HIV-infected patients, the -1131C carriers in APOA5 gene experienced marked increases in triglyceride levels (up to 80%) during a 3-year follow-up, while no change was recorded in patients carrying the normal -1131T allele. More recent studies [23,24] have associated nucleotide variations in resistin and β2 adrenergic receptor (ARβ2) with the occurrence of lipodystrophy. In addition, tumor necrosis factor-α (TNFa) [20,25,26] and nuclear transcription-
Figure 1 Lipid profile changes in patients receiving PI therapy. Carriers of the A allele (closed circles) had significantly increased serum triglyceride (A) and total cholesterol (B) concentrations together with depressed levels of HDL-cholesterol (C) when compared with non-carriers (open circles) at 3, 6, and 12 months after treatment initiation. * indicates p < 0.05.

Figure 2 Lipid profile changes in patients receiving NNRTI therapy. No differences were observed between genotypes in regards to serum triglyceride (A) or total cholesterol (B) concentrations. However, carriers of the A allele (closed circles) had significantly decreased HDL-cholesterol values when compared with non-carriers (open circles) at 3, 6, and 12 months after treatment initiation (C). * indicates p < 0.05.
factor sterol response element-binding protein 1c (SREBP1c) [27,28] have also been shown to affect HIV-induced lipodystrophy, but confirmation is required in long-term prospective studies.

The intriguing results obtained by Pollin et al. [5] in the polymorphism rs10892151, which is located 800 kb from the APOC3 gene cluster, prompted us to test the presence of a genetic association with lipid outcomes in our patients. In their high-fat feeding intervention study in 809 Old Order Amish individuals, the authors observed that rs10892151 A carriers had lower fasting concentrations for patients with the G/A genotype. However, further studies in larger populations under prospective studies.

High serum triglyceride concentration and low HDL-cholesterol values were found in our population, irrespective of the treatment they were assigned (although the effect was notably higher in those patients under PI treatment), but these lipid disorders were not related to a differential or abnormal response to circulating apo C-III values in either HIV-infected patients or healthy subjects, indicating that the linkage disequilibrium between this two genetic regions could not be universal.

Although the design of our study cannot address the mechanism by which antiretroviral treatment and HIV-infection interact with the polymorphism, it could be argued that antiretroviral treatment may interfere in the functioning of lipolytic enzymes, [29,30] which are regulated by serum apo C-III concentrations, decreasing the catabolism of triglyceride-rich proteins in carriers of the rs10892151 A allele. However it does not explain why antiretroviral treatment and rs10892151 genetic variation have a limited impact on apo C-III levels, probably masked by the concomitant metabolic effects described during HIV infection. Despite the fact that our HIV-infected patients showed higher levels of apo C-III than healthy controls, the described effect was influenced by rs10892151 genotype rather than by serum apo C-III concentration. It is also noteworthy that there is a highly significant gene-nutrient interaction and that dietary manipulation may modulate the effect of polymorphisms on lipid profile [31].

Another possibility is that antiretroviral treatment may not affect just lipoprotein metabolism, but may exacerbate the chronic inflammatory state by the expression of pro-inflammatory molecules such as TNFα or MCP-1, which have a major role in lipid metabolism and, consequently, in cardiovascular disease [14,32-34]. However, this hypothesis is not supported by our findings that the plasma MCP-1 and CRP concentrations were essentially the same in both groups of HIV-infected patients as well as in both genotypes.

The peculiar distribution of alleles seriously limits the reach of our conclusions but the differential response and pharmacogenetic implications among patients with different treatment strongly reinforces the need for replication. According to our data, this should be done in a sample with same ethnic origin and a sample size only achievable in multicenter-multicohort studies. The impact of population stratification in this study is unlikely because in our population sample this has been already assessed empirically by analyzing more than 25 unlinked single-nucleotide polymorphisms (SNPs) in several association studies spanning a range of disease states [35-39] and cases selected under the same circumstances.

We also acknowledge that studies assessing only one polymorphism are less robust than those assessing several polymorphisms associated with a plausible role in the pathogenesis of dyslipidemia. Further studies are needed to assess the possibly coordinated association with other well-documented polymorphisms, particularly those involved in metabolism and in molecular targets of antiretroviral drugs in order to uncover a host-related predisposition towards developing metabolic complications. If successful this may aid for specific, individual design of antiretroviral regimens to diminish the rapid emergence of side effects and the consequent deleterious significance.

Conclusions

These results suggest that the rs10892151 A allelic variant could be associated in HIV-infected patients with less favorable lipid profile, particularly those treated with PIs. The exact mechanism for this putative effect is unknown but, considering the therapeutic implications, clarification deserves further research.
Acknowledgements

The authors are indebted to Dra. Núria Canela for her invaluable technical assistance.

This work was financially supported by the Fondo de Investigación Sanitaria (FIS PI08/1032).

Author details

1Centre de Recerca Biomèdica, Universitat Rovira i Virgili, Institut d’Investigació Sanitària Pere Virgili (ISPV), Reus, Spain. 2Servei de Medicina Interna, Hospital Son Llàtzer, Palma, Illes Balears, Spain. 3Servei de Medicina Interna, Hospital Universitari de Sant Joan, Institut d’Investigació Sanitària Pere Virgili (ISPV), Reus, Spain.

Authors’ contributions

JJ and CA-V conceived and designed the study and reviewed critically the manuscript. GA and PP-R performed the statistical analysis and drafted the manuscript. AR, RB-D, ER-G and LF-S collated data or performed various measurements for the study and helped with the analysis and interpretation of the data. JC reviewed critically the manuscript. All authors read and approved the final version of the manuscript.

Competing interests

The authors declare that they have no competing interests.

Received: 26 May 2011 Accepted: 22 September 2011

Published: 22 September 2011

References

1. Monsuez JJ, Charniot JC, Escaut L, Teicher E, Wyplosz B, Couzigou C, Vignat N, Vitré JF: HIV-associated vascular diseases: structural and functional changes, clinical implications. Int J Cardiol 2009, 133:295-306.

2. Fisher SD, Miller TL, Lipshultz SE: Lipid abnormalities in patients infected with HIV are associated with a more rapid onset of lipodystrophy. J Acquir Immune Defic Syndr 2001, 27:121-123.

3. Clavery V, Lestavel-DeLattre S, Copin C, Bard JM, Fruchart JC: Modulation of lipoprotein B binding to the LDL receptor by exogenous lipids and apolipoproteins CII, CIII, and E. Arterioscler Thromb Vasc Biol 1995, 15:963-971.

4. Chan DC, Nguyen MN, Watts GF, Barrett PH: Plasma apolipoprotein C-III transport in centrally obese men: associations with very low-density lipoprotein apolipoprotein B and high-density lipoprotein apolipoprotein A-I metabolism. J Clin Endocrinol Metab 2008, 93:557-564.

5. Kawakami A, Aikawa M, Libby P, Alcaine P, Lucinskas FW, Sacks FM: Apolipoprotein CIII in apolipoprotein B lipoproteins enhances the adhesion of human mononcytic cells to endothelial cells. Circulation 2006, 113:691-700.

6. Libby P: Fat fuels the flame: triglyceride-rich lipoproteins and arterial inflammation. Circ Res 2007, 100:299-301.

7. Schambelan M, Benson CA, Carr A, Currier JS, Dubé MP, Gerber JG, Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS:

Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257-275.

8. Coll B, Alonso-Villaverde C: Carotid intima-media thickness: assessment of sub-clinical atherosclerosis in HIV-infected patients. AIDS 2005, 19:1956-1957.

9. Alonso-Villaverde C, Coll B, Parra S, Montero M, Calvo N, Tous M, Joven J, Masana L: Atherosclerosis in patients infected with HIV is influenced by a mutant monocyte chemoattractant protein-1 allele. Circulation 2004, 110:2204-2209.

10. Féret J, Campos J, Fernández-Ballart Arija V, Murphy MM, Ceruelo S, Briánès E, Wellà E, Tous M, Joven J: Regulation of serum paraoxonase activity by genetic, nutritional and lifestyle factors in general population. Clin Chem 2003, 49:1491-1497.

11. Simó JM, Castellano I, Ferré N, Joven J, Camps J: Evaluation of a homogeneous assay for high-density lipoprotein cholesterol: limitations in patients with cardiovascular, renal, and hepatic disorders. Clin Chem 1994, 40:1233-1241.

12. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 1972, 18:499-502.

13. Shen GQ, Abdullah KG, Wang QK: The TaqMan Method for SNP genotyping. Methods Mol Biol 2009, 578:295-306.

14. Ledergerber B, Telenti A, Swiss HIV Cohort Study: Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders. J Infect Dis 2005, 191:1419-1426.

15. Bonnet E, Jauvet J, Fauvet J, Massip P, Rudavets JB, Perret B: Association of APOC3 polymorphisms with both dyslipidemia and lipidostrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 2008, 24:169-171.

16. Guardiola M, Ferré R, Salazar J, Alonso-Villaverde C, Coll B, Parra S, Masana L, Ribaltà J: Protease inhibitor-associated dyslipidemia in HIV-infected patients is strongly influenced by the APOA1-1131T>C gene variation. Clin Chem 2006, 52:1914-1919.

17. Tarr PE, Taffet P, Bleiber G, Furrer H, Rotger M, Martinez R, Hirschel B, Battegay M, Weber R, Vennazza P, Bernaioni E, Datioli R, Rickenbach M, Ledergerber B, Telenti A, Swiss HIV Cohort Study: Association of apolipoproteins C3 and E with metabolic changes in HIV-infected adults treated with a protease-inhibitor-containing antiretroviral therapy. Antivir Ther 2006, 11:361-370.

18. Ranade K, Geese WJ, Noroo M, Flint O, Tebas P, Mulligan K, Powdrley W, Grinspoon SK, Dubé MP: Genetic analysis implicates resistin in HIV lipodystrophy. AIDS 2008, 22:1561-1568.

19. Zanone Poma B, Riva A, Nasi M, Cocconi P, Brogini V, Lepri AC, Molinogi D, Mazzotta F, Monforte AD, Mussini C, Cossarizza A, Galli M, Icona Foundation Study Group: Genetic polymorphisms differentially influencing the emergence of atrophy and fat accumulation in HIV-infected patients. AIDS 2008, 22:1769-1778.

20. Maher B, Affrètic A, Vilar FJ, Williams EZ, Park BK, Pirmohamed M: TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 2002, 16:2013-2018.

21. Nolan DJ, Moore C, Castle A, Sayer D, Marnotte C, John M, Mallal S, Mucilla S, Tumour necrosis factor-alpha gene -383G/A in HIV-infected White South African patients is strongly associated with the emergence of atrophy and fat accumulation in HIV-infected patients. AIDS 2008, 22:1769-1778.

22. Miserez AR, Müller PY, Barella L, Schwietert M, Erb P, Vernazza P, Battegay M, Swiss HIV Cohort Study: Association of APOC3 polymorphisms with both dyslipidemia and lipidostrophy in HAART-receiving patients. AIDS Res Hum Retroviruses 2008, 24:169-171.

23. Jansen H, Chu G, Ehnholm C, Dalongeville J, Nicoud V, Talmud PJ: The TaqMan Method for SNP genotyping. Methods Mol Biol 2009, 578:295-306.

24. Jansen H, Chu G, Ehnholm C, Dalongeville J, Nicoud V, Talmud PJ: The TaqMan Method for SNP genotyping. Methods Mol Biol 2009, 578:295-306.

25. Haakonson J, Jóhannesson H, Thórsdóttir I: Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 2006, 185:1-11.

26. Umpleby AM, Das S, Stolarski M, Shojaei-Moradie F, Jackson NC, Jefferson W, Crabtree N, Nightingale P, Shahnamehr M: Low density lipoprotein apolipoprotein B metabolism in treatment-naive HIV patients and patients on antiretroviral therapy. Antivir Ther 2005, 10:663-670.

27. Bonnet E, Genoux A, Bernard J, Fauvet J, Massip P, Perret B: Impact of genetic polymorphisms on the risk of lipid disorders in patients on anti-HIV therapy. Clin Chem Lab Med 2007, 45:815-21.

28. Pullin T, Damcott CM, Shen H, Ott SH, Shelton J, Horenstein RB, Port W, McNelis JC, Belak LF, Perry PA, Mitchell BE, Miller M, O’Connell JR, Shuldiner AR: A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection. Science 2008, 322:1702-1705.

29. Jongs MC, Hofker MH, Havekes LM: Role of ApoC in lipoprotein metabolism: functional differences between ApoC1, ApoC2, and ApoC3. Arterioscler Thromb Vasc Biol 1999, 19:472-484.

30. Grinspoon SK, Grunfeld C, Kotler DP, Mulligan K, Powderly WG, Saag MS:...
postprandial Lp C-III: B: European Atherosclerosis Research Study (EARS) II. Arterioscler Thromb Vasc Biol 1999, 9:303-308.
31. Ordovas JM, Corella D, Demissie S, Cupples LA, Couture P, Coltell O, Wilson PW, Schaefer EJ, Tucker KL: Dietary fat intake determines the effect of a common polymorphism in the hepatic lipase gene promoter on high-density lipoprotein metabolism: evidence of a strong dose effect in this gene–nutrient interaction in the Framingham Study. Circulation 2002, 106:2315-21.
32. Jovinge S, Hamsten A, Tornvall P, Proudler A, Blivenholm P, Ericsson CG, Godsland I, de Faire U, Nilsson J: Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease. Metabolism 1998, 47:113-118.
33. Rull A, Escolá-Gil JC, Juve J, Rottländer N, Calpe-Berdiel L, Coll B, Aragonés G, Marsillach J, Alonso-Villaverde C, Camps J, Bianco-Vaca F, Joven J: Deficiency in monocyte chemoattractant protein-1 modifies lipid and glucose metabolism. Exp Mol Pathol 2007, 83:361-366.
34. Appay V, Sauce D: Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008, 214:231-241.
35. Alonso-Villaverde C, Aragonés G, Beltrán-Debón R, Fernández-Sender L, Rull A, Rodríguez-Sanabria F, Marsillach J, Pardo-Reche P, Camps J, Joven J: Host-pathogen interactions in the development of metabolic disturbances and atherosclerosis in HIV infection: the role of CCL2 genetic variants. Cytokine 2010, 51:351-8.
36. Parra S, Marsillach J, Aragonés G, Beltrán R, Montero M, Coll B, Mackness B, Mackness M, Alonso-Villaverde C, Joven J, Camps J: Paraoxonase-1 gene haplotypes are associated with metabolic disturbances, atherosclerosis, and immunologic outcome in HIV-infected patients. J Infect Dis 2010, 201:627-34.
37. Coll B, Parra S, Alonso-Villaverde C, Aragonés G, Montero M, Camps J, Joven J, Masana L: The role of immunity and inflammation in the progression of atherosclerosis in patients with HIV infection. Stroke 2007, 38:2477-84.
38. Alonso-Villaverde C, Coll B, Gómez F, Parra S, Camps J, Joven J, Masana L: The efavirenz-induced increase in HDL-cholesterol is influenced by the multidrug resistance gene 1 C3435T polymorphism. AIDS 2005, 19:341-2.
39. Pritchard JK, Rosenberg NA: Use of unlinked genetic markers to detect population stratification in association studies. Am J Hum Genet 1999, 65:220-228.

Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2350/12/120/prepub

doi:10.1186/1471-2350-12-120
Cite this article as: Aragonès et al.: Antiretroviral treatment-induced dyslipidemia in HIV-infected patients is influenced by the APOC3-related rs10892151 polymorphism. BMC Medical Genetics 2011 12:120.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit